CA3020243A1 - Exosomes portant un micro-arn qui cible la proteine cellulaire infectee-4 (icp4), compositions pharmaceutiques et methodes de traitement d`une infection causee par le virus de l`herpes simplex (vhs) - Google Patents

Exosomes portant un micro-arn qui cible la proteine cellulaire infectee-4 (icp4), compositions pharmaceutiques et methodes de traitement d`une infection causee par le virus de l`herpes simplex (vhs) Download PDF

Info

Publication number
CA3020243A1
CA3020243A1 CA3020243A CA3020243A CA3020243A1 CA 3020243 A1 CA3020243 A1 CA 3020243A1 CA 3020243 A CA3020243 A CA 3020243A CA 3020243 A CA3020243 A CA 3020243A CA 3020243 A1 CA3020243 A1 CA 3020243A1
Authority
CA
Canada
Prior art keywords
exosome
exo
motif
seq
icp4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3020243A
Other languages
English (en)
Inventor
Xiaoqing Chen
Bernard Roizman
Grace Guoying ZHOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immvira Co Ltd
Original Assignee
Immvira Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immvira Co Ltd filed Critical Immvira Co Ltd
Priority to CA3020243A priority Critical patent/CA3020243A1/fr
Publication of CA3020243A1 publication Critical patent/CA3020243A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3020243A 2018-10-09 2018-10-09 Exosomes portant un micro-arn qui cible la proteine cellulaire infectee-4 (icp4), compositions pharmaceutiques et methodes de traitement d`une infection causee par le virus de l`herpes simplex (vhs) Abandoned CA3020243A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3020243A CA3020243A1 (fr) 2018-10-09 2018-10-09 Exosomes portant un micro-arn qui cible la proteine cellulaire infectee-4 (icp4), compositions pharmaceutiques et methodes de traitement d`une infection causee par le virus de l`herpes simplex (vhs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA3020243A CA3020243A1 (fr) 2018-10-09 2018-10-09 Exosomes portant un micro-arn qui cible la proteine cellulaire infectee-4 (icp4), compositions pharmaceutiques et methodes de traitement d`une infection causee par le virus de l`herpes simplex (vhs)

Publications (1)

Publication Number Publication Date
CA3020243A1 true CA3020243A1 (fr) 2020-04-09

Family

ID=70155979

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020243A Abandoned CA3020243A1 (fr) 2018-10-09 2018-10-09 Exosomes portant un micro-arn qui cible la proteine cellulaire infectee-4 (icp4), compositions pharmaceutiques et methodes de traitement d`une infection causee par le virus de l`herpes simplex (vhs)

Country Status (1)

Country Link
CA (1) CA3020243A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089382A1 (fr) * 2020-10-26 2022-05-05 Immvira Co., Limited Exosomes contenant des miarn ciblant la synthèse de her2 et compositions pharmaceutiques
CN114703271A (zh) * 2022-01-26 2022-07-05 无锡市妇幼保健院 一种调控ICP过程中胎盘滋养细胞凋亡与增殖的LncRNA及其应用

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089382A1 (fr) * 2020-10-26 2022-05-05 Immvira Co., Limited Exosomes contenant des miarn ciblant la synthèse de her2 et compositions pharmaceutiques
CN114703271A (zh) * 2022-01-26 2022-07-05 无锡市妇幼保健院 一种调控ICP过程中胎盘滋养细胞凋亡与增殖的LncRNA及其应用

Similar Documents

Publication Publication Date Title
Mulik et al. Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus
KR20180096593A (ko) 단순 포진 바이러스 백신
JP2019517815A (ja) 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現
CN111770758A (zh) 用于治疗Angelman综合征的方法和组合物
WO2017062659A1 (fr) Compositions et procédés pour traiter la rétinopathie diabétique
US20100041734A1 (en) Modulation of toll-like receptor 7 expression by antisense oligonucleotides
CA3020243A1 (fr) Exosomes portant un micro-arn qui cible la proteine cellulaire infectee-4 (icp4), compositions pharmaceutiques et methodes de traitement d`une infection causee par le virus de l`herpes simplex (vhs)
JP7362156B2 (ja) 腫瘍を治療するための医薬組成物、キット及び方法
CN113227384B (zh) 用于治疗肿瘤的药物组合物、药盒和方法
CN113056560B (zh) 能够实现反馈的合成基因、靶点种子匹配盒及其应用
US10537591B2 (en) Method for promoting muscle regeneration
CN110462032B (zh) 作为病毒抑制的靶标的pum1蛋白
WO2013088853A1 (fr) Oligonucléotide, activateur de sensibilité aux glucocorticoïdes, composition de médicament et vecteur d'expression
CN110964851B (zh) 组蛋白修饰酶基因setd8在抗dna病毒中的应用
JP6857730B2 (ja) ＣＤＫ９を標的とするＲＮＡｉエフェクターを発現するＨ−１ ＰＶ
US20230047473A1 (en) siRNA based on RNA sequence of SARS-CoV-2 and use thereof
KR20230069219A (ko) HER2를 표적화하여 합성된 miRNA를 함유하는 엑소좀 및 약물 조성물
CN117224576A (zh) 靶向CSF1R的miRNA与溶瘤单纯疱疹病毒的组合疗法
CN118304317A (en) Preparation method of novel coronavirus inhibitor
JP2023013932A (ja) ＳＡＲＳ－ＣｏＶ－２ ＲＮＡ配列に基づく新規ｓｉＲＮＡ及びその利用
EP4052720A2 (fr) Formules d'alicaforsen
US20240132891A1 (en) Microrna compositions and methods of use thereof for the treatment of nervous system dysfunction
US20240229031A9 (en) Microrna compositions and methods of use thereof for the treatment of nervous system dysfunction
JP2023548746A (ja) サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
TW202304948A (zh) 強直性肌肉營養不良１型治療藥

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211220

FZDE Discontinued

Effective date: 20211220